MPM Capital and Qiming Venture Partners USA have co-led a series A round for Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute.

Umoja Biopharma, a US-based in-vivo immunotherapy platform developer exploiting research from Purdue University and Seattle Children’s Research Institute, launched with a $53m series A round on Wednesday co-led by MPM Capital and Qiming Venture Partners USA. Founded in early 2019, Umoja is working on an integrated in-vivo immunotherapy platform targeting blood cancers and solid tumours,…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.